Imugene Limited - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Imugene Limited Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Imugene Limited. The Group's principal activities are researching, developing and commercialising animal health technologies. Products include Poultry Productivity Enhancer, Avian Influenza (Bird Flu) Poultry, Coccidiosis, Classical Swine Fever and Porcine Reproductive and Respiratory Syndrome (PRRS) vaccine. Its vaccines are developed from two platform technologies, namely, the fowl adenovirus (FAV) and porcine adenovirus (PAV). Its products improve the health and welfare of animals and reduce or eliminate the use of chemicals and drugs, particularly antibiotics, in production animals. Operations are carried out in Australia.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report